Navigation Links
New non-surgical treatment for common, vexing eye condition
Date:3/31/2014

Baltimore, MD, 31 March 2014. A new report reveals a potential breakthrough in the treatment of a common eye ailment known as pterygium (Surfer's eye) that impacts the vision, eye health, and cosmetic appearance of countless sufferers.

The newly published report shows that eye drops containing the anti-anginal drug dipyridamole (Persantin, Cardoxin) led to almost total disappearance of an inflamed pterygium in a 35 year old otherwise healthy woman.

Dipyridamole is a drug in use over the past 55 years to treat other disorders, but now found to have this remarkable new use.

Pterygium is a disorder in which a non-cancerous growth develops on the white conjunctiva of the eye and over time invades the cornea. In some countries it affects up to 25% of the population. As the growth spreads, patients can develop vision problems as well as significant discomfort from complications such as dry eye, inflammation, irritation, and foreign body sensation. Additionally, because of their location in the eyes, pterygia are a cause of substantial cosmetic concern for sufferers.

Until now, eye surgery has been the only curative option, aided by medications trying to lessen the disorder's symptoms. However, even after eye surgery, pterygia often recur.

The new report's lead author, Moshe Rogosnitzky, who is Co-Founder and Director of Research at the MedInsight Research Institute, discovered that administration of dipyridamole eye drops significantly reduced a pterygium and completely resolved the associated inflammation and other symptoms.

Clinical trials are now being plannedfor pterygia, pingueculae, and other common eye disorders and their complications such as dry eye and inflammation.

One particular advantage to this discovery is that dipyridamole is a widely-approved anti-thrombosis medication that has been in use for over 55 years. Its safety profile is well-established; as such, fast-track development of dipyridamole eye drops as a repurposed drug is feasible.

Moshe Rogosnitzky commented on this finding, "Pterygium and dry eye are debilitating disorders for which new safe solutions are urgently needed, and I believe dipyridamole has the potential to provide relief to sufferers of these intractable conditions.

Rogosnitzky, who specializes in finding new uses for old drugs, continued, "This is yet another example of the advantages of drug repurposing. Whereas bringing a new drug to market can take up to 17 years or more, finding a new use for an old drug with an excellent safety profile can lead to approval and availability in as little as two years."


'/>"/>
Contact: Deena Illions
deena1@medinsight.org
443-927-7755
MedInsight Research Institute
Source:Eurekalert  

Related medicine news :

1. Masha Banar, Board Certified Physician Associate, Now Offers Non-Surgical Rhinoplasty for Correction of Complications After Surgical Rhinoplasty
2. Cosmetic Laser Institute in Orange County Introduces Non-Surgical Fat Reduction with Exilis
3. Barnes-Jewish Hospital Offering New FDA-approved Non-surgical Procedure for Mitral Valve Repair
4. Lipo Body Sculpture of Houston Announces Breakthrough Treatment for Non-Surgical Neck Tightening
5. Masha Banar, PA-C of Visage Sculpture, Non-surgical Face Shaping Cosmetic Practice of Boston, Confirms Resistance Forming to Botox over Time, Less to Dysport.
6. Non-surgical Facelift, Specialty of Masha Banar PA-C of Visage Sculpture, Got a "Lift": Retrospective Comparison of Radiesse, Sculptra, and Perlane
7. Horwitz Dermatology Now Offers Non-Surgical Ultrasound Skin Tightening Treatments
8. Brandith Irwin, MD, of SkinTour.com Answers New Blog Question About Improving Neck Skin Non-Surgically
9. Visage Sculpture, Non-Surgical Face Shaping Cosmetic Practice of Boston, Announces Using Microcannulas to Make Non-Surgical Rhinoplasty Safer
10. Living Well Medical Introduces Groundbreaking Non-Surgical Therapies for Osteoarthritis Knee Pain
11. Dr. Leslie Gerstman Is Now Offering the Non-surgical Facelifting Procedure – Ultherapy – in NYC and NJ
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New non-surgical treatment for common, vexing eye condition
(Date:2/11/2016)... ... ... Journal of Pain Research has seen a significant increase in its ranking ... Scopus database (Elsevier B.V.) and is a measure of a journal's impact. It takes ... year period and also the importance of the journals where the citations came from. ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... will discuss how to improve care by making data on heart procedures public ... The Summit on Transparency and Public Reporting of Pediatric and Congenital Heart Disease ...
(Date:2/11/2016)... NJ (PRWEB) , ... February 11, 2016 , ... ... the call for nominations seeking candidates for the Board of Commissioners. Individuals interested ... passion, skills and experience with diversity of clinical practice settings and across allied ...
(Date:2/11/2016)... ... February 11, 2016 , ... Colorado spine surgeon, Donald Corenman, ... 334 spine surgeons to know in 2016 . The list consists of spine surgeons ... surgery. , Dr. Corenman understands the importance of clinical excellence; he has been ...
(Date:2/11/2016)... ... February 11, 2016 , ... The annual list showcases the ... of DataPoint’s team dedication and commitment to the SharePoint ecosystem. A panel ... list. The panel’s goal is to recognize and promote technology entrepreneurship. , The ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Scientists from Silicon Biosystems Menarini today ... door to genetic analysis of previously preserved tumor ... isolate with 100 percent purity. Utilizing the com­pany,s ... various stages of development, the researchers were able ... are clinically relevant, and may change the way ...
(Date:2/11/2016)... 11, 2016  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ... made at the 38th annual John A. Boswick ... which is being held February 14-18, 2016 in ... latest advancements in wound healing, burn care, and infection ... Australian-New Zealand Burns Association, Academy of Physicians in Wound ...
(Date:2/11/2016)... 2016  Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced ... a Controlled Equity Offering SM Sales Agreement with ... Macaluso , Chairman and CEO, stated "During our most ... currently raising money and that we have enough money ... still complete all of our current objectives and nothing ...
Breaking Medicine Technology: